Acorda Therapeutics Inc. kicked off the trading day on 10/10/19 with a price decrease of -6.64%, equivalent to -$0.19 relative change for the day. Taking a more long-term approach, ACOR had a 52-week range of $2.27 to $21.63. At the time of this article’s publishing, this stock is trading at $2.67 after starting the trading session at $2.87. At the time of writing, this stock’s 50-day Moving Average stands at $3.18, while the 200-day Moving Average of this stock is currently $9.67.
Currently, this company’s share volume is sitting at $1546760, but has maintained average daily volume of $1.67M. This stock has generated an average Year to Date volume of $1.15 million, alongside an average 20-day volume of $1.49 million. This publicly-traded company’s shares outstanding now amounts to $47.49 million, simultaneously with a float of $47.38 million. The organization now has a market capitalization sitting at $126.79 million.
Acorda Therapeutics Inc.(ACOR) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Acorda Therapeutics Inc.’s current insider ownership accounts for 1.85%. According to the most recent latest insider trade that took place on Feb 22 this organization’s Chief Commercial Officer sold 761 at the rate of 13.18, making the entire transaction hit 10,028 in total value, affecting insider ownership by 5,092. Preceding that transaction, on Feb 22 Company’s Chief, Bus. Ops & PAO sold 761 at a price of 13.18, making the whole transaction’s value amount to 10,028. This particular insider is now the holder of 5,092 in total.
All together, they are the legal holders of 47.49M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Fidelity Management & Research Co. owns 7,002,174 shares, with BlackRock Fund Advisors in 2nd place owning 6,447,259 shares and The Vanguard Group, Inc. in third place with total ownership of 6,148,451 shares.
Acorda Therapeutics Inc. (ACOR) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported -$0.55 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$1.06) by $0.51.
This company achieved a net margin of -25.94 while generating a return on equity of -13.56. Acorda Therapeutics Inc.’s full-quarter revenue decreased by -65.69%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year.
Acorda Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 108.70%, and is forecasted to reach -2.94 in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 29.00% through the next 5 years, which can be compared against the 0.20% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Acorda Therapeutics Inc., this organization’s Quick Ratio in the last reported quarter now stands at 3.50. The company has managed to achieve an average true range (ATR) of 0.32. Alongside those, its Beta score is 1.23.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.41 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 0.23, whereas its price to cash per share for the last quarter landed at 6.25.
In the same vein, ACOR’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -1.98, a figure that is expected to reach -0.78 in the next reported quarter, and analysts expect it will be -2.94 at the market close of one year from today’s date.